Immunotherapy of metastatic renal cell cancer

Cancer Control

Volumn 9, Issue 4, 2002, Pages 293-304

  Fishman, Mayer ^a   Seigne, John ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; B7 ANTIGEN; BAY 504798; BEVACIZUMAB; CD40 ANTIGEN; CYTOKINE; CYTOTOXIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HYBRID PROTEIN; INTERLEUKIN 2; INTERLEUKIN 2 DERIVATIVE; INTERLEUKIN 6; LEUVECTIN; MACROGOL; MELACINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G250; PROTEIN; PROTEIN ANTIBODY; PROTEIN HUKS; PROTEIN L19; PROTEIN MN CA9; RECOMBINANT ALPHA2B INTERFERON; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; KIDNEY CARCINOMA; LYMPHOCYTE TRANSFER; MEDICAL LITERATURE; METASTASIS; NEPHRECTOMY; NONHUMAN; REVIEW;

EID: 0036638978     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900404     Document Type: Review

References (98)

1. Increased incidence of serendipitously discovered renal cell carcinoma
2. Rising incidence of renal cell cancer in the United States
3. Increasing incidence of all stages of kidney cancer in the last 2 decades in the United States: An analysis of surveillance, epidemiology and end results program data
4. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
5. Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell carcinoma
6. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy
7. Long-term survival update for high-close recombinant interleukin-2 in patients with renal cell carcinoma
8. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: Evidence of impaired secretion in response to interleukin-12
9. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma
10. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy
11. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer
12. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor
13. Renal cell carcinoma: Natural history and results of treatment
14. The failure of infarction and/or nephrectomy in stage IV renal cell cancer to influence survival or metastatic regression
15. Nephrectomy in metastatic renal cell carcinoma
16. Renal-cell carcinoma
17. Metastatic renal cell cancer and radical nephrectomy: Identification of prognostic factors and patient survival
18. Pulmonary resection of metastatic renal cell carcinoma
19. Long-term results after pulmonary resection of renal cell carcinoma metastases
20. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer
21. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: A randomised trial
22. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma
23. Mathematical model to predict individual survival for patients with renal cell carcinoma
24. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: Long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy
25. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: A pilot study
26. Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place
27. Influence of tumor size and surgical resection on cell-mediated immunity in mice
28. Evolution of cellmediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal, and treatment with irradiated tumor cells
29. In vitro assessment of cell-mediated immunity in patients with renal cell carcinoma
30. Guidelines for the safe administration of high-dose interleukin-2
31. High-dose bolus interleukin-2 in a non-intensive care unit setting for metastatic renal cell carcinoma (RCCa): UCLA Kidney Cancer Program
32. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma
33. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma
34. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil
35. Infusional interleukin-2 and 5fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: A Southwest Oncology Group phase II study
36. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: Long-term results of a controlled randomized clinical trial
37. A randomized phase III trial of high-dose interleukin-2 (HD IL2) versus subcutaneous (SC) I12/interferon (IFN) in patients with metastatic renal cell carcinoma (RCC)
38. Interferon in metastatic renal cell carcinoma
39. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer
40. Paroxetine for the prevention of depression induced by high-dose interferon alfa
41. Expression of type I interferon receptor in renal cell carcinoma
42. Human renal cancers resistant to IFNs antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions
43. Increased soluble interleukin-2 receptor concentration in plasma predicts a decreased cellular response to IL-2
44. Molecular analysis of the IL-2 receptor beta chain gene expressed in human tumor cells
45. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Antiangiogenic effect on HPV-harboring tumor-cell lines
46. Inhibition of angiogenesis and vascular tumor growth by interferon-producing cells: A gene therapy approach
47. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma
48. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised controlled trial
49. Updated results of the MRC randomised controlled trial of alpha interferon vs MPA in patients with metastatic renal carcinoma
50. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: A multicentric randomized study
51. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma
52. Survival in renal cell carcinoma-a randomized evaluation of tamoxifen vs interleukin 2, alpha-interferon (leucocyte) and tamoxifen
53. Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-alpha
54. Immunomodulation by thalidomide and thalidomide analogues
55. Theoretical basis for the activity of thalidomide
56. Intratumoral interleukin 2 for renalcell carcinoma by direct gene transfer of a plasmid DNA/DMRIE/DOPE lipid Complex
57. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex
58. Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma
59. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2
60. Delivery of cytokines by liposomes: Hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes
61. AT-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo
62. Recombinant interleukin-2 in combination with recombinant interferon-gamma in patients with advanced malignancy: A phase 1 study
63. Sequential administration of interferon-gamma, GM-CSF, and interleukin-2 in patients with metastatic renal cell carcinoma: Results of a phase II trial
64. Sequential administration of interferon gamma and interleukin-2 in metastatic renal cell carcinoma: Results of a phase II trial
65. Phase I-II study of gamma interferon and 5-fluorouracil for patients with metastatic renal cell carcinoma
66. Placebo-associated remissions in a multicentre, randomized, double-blind trial of interferon gamma-1b for the treatment of metastatic renal cell carcinoma
67. A randomized phase II trial comparing two different sequence combinations of autologous vaccine and human recombinant interferon gamma and human recombinant interferon alpha2B therapy in patients with metastatic renal cell carcinoma: Clinical outcome and analysis of immunological parameters
68. Phase I trial of simultaneously administered GM-CSF and IL-6 in patients with renal-cell carcinoma: Clinical and laboratory effects
69. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma
70. Novel therapies for renal cell carcinoma
71. Agranulocytosis and hemolytic anemia in patients with renal cell cancer treated with interleukin-12
72. Construction of evolutionary tree models for renal cell carcinoma from comparative genomic hybridization data
73. HSPPC-96: A personalised cancer vaccine
74. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma
75. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer
76. Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney
77. Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250
78. Chimeric G250 (cG250) monoclonal antibody Phase I dose escalation trial in patients with advanced renal cell carcinoma (RCC)
79. The expression of epidermal growth factor receptor and transforming growth factor alpha in renal cell carcinoma
80. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer (RCC)
81. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo
82. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
83. A randomized double-blind placebo-controlled trial of bevacizumab (anti-VEGF antibody) demonstrating a prolongation in time to progression in patients with metastatic renal cancer
84. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents
85. Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix
86. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokineprimed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor
87. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma
88. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: Long-term results
89. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer
90. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
91. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma
92. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: Feasibility, engraftment, and clinical results
93. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation